← Leaderboards

Raymond F. Schinazi

Emory University

Google Scholar ↗PubMed ↗ORCID ↗

$18,319,973

Attributed

$28,110,930

Total exposure

32

Grants

26

Lead (contact PI)

Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.

Funding over time

peak $3.7M · FY2005–25

$5M$3.8M$2.5M$1.3M$0

'05

'06

'07

'08

'09

'10

'11

'12

'13

'14

'15

'16

'17

'18

'19

'20

'21

'22

'23

'24

'25

Funding mix

By agency

NIH$28,110,930 · 31

VA$0 · 1

By mechanism

R01$22,585,377 · 9

R37$2,144,340 · 1

P30$1,401,888 · 2

P51$674,817 · 7

R56$635,652 · 1

R21$429,000 · 1

Top collaborators

Most similar at Emory University

Same institution · by research overlap

Rama Rao Amara$90,840,294
Stefan G Sarafianos$26,943,765
Haian Fu$16,783,892
Rafi Ahmed$104,632,759
Kimberlynn Becnel Davis$25,581

Others in their field

Top investigators on “Viral”

Lawrence Corey · Fred Hutchinson Cancer Center$466,994,927
David Heimbrook · Leidos Biomedical Research, Inc.$366,090,791
Daniel R Kuritzkes · Brigham And Women'S Hospital$267,074,199
Glenda E Gray · Wits Health Consortium (Pty), Ltd$252,763,614
Judith S. Currier · University Of California Los Angeles$185,434,785
Constance Ann Benson · University Of California, San Diego$165,517,633

Research focus

ViralVirusAntiviral AgentsPharmaceutical PreparationsVirus ReplicationDesignOralPharmacologyResistanceInfectionNovel TherapeuticsCellsToxic EffectProgramsIn VitroLeadDrug KineticsIn VivoAntiretroviral TherapyVaccinesHiv InfectionsAreaTherapeutic AgentsClinical Research

Grant awards (88)

Anti-norovirus protease inhibitors for immunocompromised patients$1,504,695

R01 · FY2025 · AI · contact PI

Discovery of Antivirals Targeting Mpox Virus$767,057

R01 · FY2025 · AI

HBV Capsid Effectors$702,799

R01 · FY2025 · AI · contact PI

Broad-spectrum therapeutics against SARS-CoV-2 3CL protease$642,901

R01 · FY2025 · AI · contact PI

HIV-DART 2024$30,000

R13 · FY2025 · AI · contact PI

Respi-DART: Frontiers in drug development against respiratory viruses and emerging viruses$5,000

R13 · FY2025 · AI · contact PI

Discovery of Antivirals Targeting Mpox Virus$782,142

R01 · FY2024 · AI

Anti-norovirus protease inhibitors for immunocompromised patients$762,258

R01 · FY2024 · AI · contact PI

Broad-spectrum therapeutics against SARS-CoV-2 3CL protease$645,603

R01 · FY2024 · AI · contact PI

HBV Capsid Effectors$632,520

R01 · FY2024 · AI · contact PI

Anti-norovirus protease inhibitors for immunocompromised patients$796,178

R01 · FY2023 · AI · contact PI

HBV Capsid Effectors$702,799

R01 · FY2023 · AI · contact PI

Broad-spectrum therapeutics against SARS-CoV-2 3CL protease$648,225

R01 · FY2023 · AI · contact PI

HIV DART and Emerging Viruses: Frontiers in Drug Development and Antiretroviral Therapies$20,000

R13 · FY2023 · AI · contact PI

RespiDART 2022: Frontiers in Drug Development against Respiratory Viruses$6,500

R13 · FY2023 · AI · contact PI

Towards Suppression and Elimination of HIV in the CNS$673,447

R01 · FY2022 · MH · contact PI

Broad-spectrum therapeutics against SARS-CoV-2 3CL protease$650,769

R01 · FY2022 · AI · contact PI

HBV Capsid Effectors$437,874

R01 · FY2022 · AI · contact PI

HEP DART 2021: FRONTIERS IN DRUG DEVELOPMENT FOR HEPATOLOGY$12,000

R13 · FY2022 · AI · contact PI

HIV DART and Emerging Viruses: Frontiers in Drug Development and Antiretroviral Therapies$1

R13 · FY2022 · AI · contact PI

Broad-spectrum therapeutics against SARS-CoV-2 3CL protease$681,379

R01 · FY2021 · AI · contact PI

Towards Suppression and Elimination of HIV in the CNS$680,675

R01 · FY2021 · MH · contact PI

HBV Capsid Effectors$635,652

R56 · FY2021 · AI · contact PI

HIV DART and Emerging Viruses: Frontiers in Drug Development and Antiretroviral Therapies$20,000

R13 · FY2021 · AI · contact PI

RespiDART & Emerging Viruses: Frontiers in Drug Development against Respiratory Viruses$5,000

R13 · FY2021 · AI · contact PI

Towards Suppression and Elimination of HIV in the CNS$691,957

R01 · FY2020 · MH · contact PI

HBV Capsid Effectors$531,433

R01 · FY2020 · AI · contact PI

SARS-CoV-2 polymerase inhibitor screening$104,001

R01 · FY2020 · AI

HEP DART 2019: Frontiers in Drug Development for Hepatology$8,500

R13 · FY2020 · AI · contact PI

HIV DART and Emerging Viruses: Frontiers in Drug Development and Antiretroviral Therapies$1

R13 · FY2020 · AI · contact PI

Towards Suppression and Elimination of HIV in the CNS$688,871

R01 · FY2019 · MH · contact PI

HBV Capsid Effectors$537,558

R01 · FY2019 · AI · contact PI

HIV DART and Emerging Viruses: Frontiers in Drug Development and Antiretroviral Therapies$20,000

R13 · FY2019 · AI · contact PI

RespiDART: Frontiers in Drug Development against Respiratory Viruses$5,000

R13 · FY2019 · AI · contact PI

Towards Suppression and Elimination of HIV in the CNS$660,576

R01 · FY2018 · MH · contact PI

HBV Capsid Effectors$543,503

R01 · FY2018 · AI · contact PI

Repurposing drugs to prevent and inhibit Zika virus inflections$195,000

R21 · FY2018 · AI · contact PI

Therapeutics Targeting Macrophages/Microglia to Eradicate CNS HIV-1 Reservoirs$728,247

R01 · FY2017 · MH · contact PI

HBV Capsid Effectors$563,003

R01 · FY2017 · AI · contact PI

Repurposing drugs to prevent and inhibit Zika virus inflections$234,000

R21 · FY2017 · AI · contact PI

Therapeutics Targeting Macrophages/Microglia to Eradicate CNS HIV-1 Reservoirs$833,525

R01 · FY2016 · MH · contact PI

Approaches Towards Eradication of Hepatitis B Virus$0

I01 · FY2016 · VA · contact PI

Therapeutics Targeting Macrophages/Microglia to Eradicate CNS HIV-1 Reservoirs$744,210

R01 · FY2015 · MH · contact PI

Therapeutics Targeting Macrophages/Microglia to Eradicate CNS HIV-1 Reservoirs$81,089

R01 · FY2015 · MH · contact PI

HIV DART: Frontiers in Drug Development for Antiretroviral Therapies$20,000

R13 · FY2015 · AI · contact PI

Approaches Towards Eradication of Hepatitis B Virus$0

I01 · FY2015 · VA · contact PI

Therapeutics Targeting Macrophages/Microglia to Eradicate CNS HIV-1 Reservoirs$649,686

R01 · FY2014 · MH · contact PI

HIV DART: Frontiers in Drug Development for Antiretroviral Therapies$1

R13 · FY2014 · AI · contact PI

Therapeutics Targeting Macrophages/Microglia to Eradicate CNS HIV-1 Reservoirs$643,687

R01 · FY2013 · MH · contact PI

HIV DART: Frontiers in Drug Development for Antiretroviral Therapies$20,000

R13 · FY2013 · AI · contact PI

Primate Model Towards HIV Eradication Strategies$705,879

R01 · FY2012 · OD · contact PI

HIV DART: Frontiers in Drug Development for Antiretroviral Therapies$1

R13 · FY2012 · AI · contact PI

Primate Model Towards HIV Eradication Strategies$705,879

R01 · FY2011 · RR

Virology and Drug Discovery$295,726

P30 · FY2011 · AI · contact PI

HIV DART: Frontiers in Drug Development for Antiretroviral Therapies$20,000

R13 · FY2011 · AI · contact PI

Primate Model Towards HIV Eradication Strategies$713,009

R01 · FY2010 · RR

Virology and Drug Discovery$325,502

P30 · FY2010 · AI · contact PI

SYNTHESIS AND BIOTRANSFORMATION OF ANTI-VIRAL PRODRUGS$65,793

P51 · FY2010 · RR · contact PI

Primate Model Towards HIV Eradication Strategies$747,943

R01 · FY2009 · RR

Virology and Drug Discovery$336,022

P30 · FY2009 · AI · contact PI

NUCLEOSIDES WITH DUAL ANTI-HIV AND HBV ACTIVITY$210,146

R37 · FY2009 · AI · contact PI

SYNTHESIS AND BIOTRANSFORMATION OF ANTI-VIRAL PRODRUGS$68,028

P51 · FY2009 · RR · contact PI

HIV DART:Frontiers in Drug Development for ARV Therapies$14,850

R13 · FY2009 · AI · contact PI

Virology and Drug Discovery$291,198

P30 · FY2008 · AI · contact PI

NUCLEOSIDES WITH DUAL ANTI-HIV AND HBV ACTIVITY$210,146

R37 · FY2008 · AI · contact PI

SYNTHESIS AND BIOTRANSFORMATION OF ANTI-VIRAL PRODRUGS$42,758

P51 · FY2008 · RR · contact PI

HIV DART:Frontiers in Drug Development for ARV Therapies$1

R13 · FY2008 · AI · contact PI

NUCLEOSIDES WITH DUAL ANTI-HIV AND HBV ACTIVITY$214,217

R37 · FY2007 · AI · contact PI

SYNTHESIS AND BIOTRANSFORMATION OF ANTI-VIRAL PRODRUGS$78,544

P51 · FY2007 · RR · contact PI

HIV DART:Frontiers in Drug Development for ARV Therapies$16,500

R13 · FY2007 · AI · contact PI

NUCLEOSIDES WITH DUAL ANTI-HIV AND HBV ACTIVITY$220,615

R37 · FY2006 · AI · contact PI

SYNTHESIS AND BIOTRANSFORMATION OF ANTI-VIRAL PRODRUGS$107,378

P51 · FY2006 · RR · contact PI

HIV DART:Frontiers in Drug Development for ARV Therapies$1

R13 · FY2006 · AI · contact PI

NUCLEOSIDES WITH DUAL ANTI-HIV AND HBV ACTIVITY$225,925

R37 · FY2005 · AI

SYNTHESIS AND BIOTRANSFORMATION OF ANTI-VIRAL PRODRUGS$94,301

P51 · FY2005 · RR

HIV DART:Frontiers in Drug Development for ARV Therapies$16,500

R13 · FY2005 · AI

NUCLEOSIDES WITH DUAL ANTI-HIV AND HBV ACTIVITY$192,000

R37 · FY2004 · AI

SYNTHESIS AND BIOTRANSFORMATION OF ANTI-VIRAL PRODRUGS$93,006

P51 · FY2004 · RR

NUCLEOSIDES WITH DUAL ANTI-HIV AND HBV ACTIVITY$72,723

R37 · FY2004 · AI

NUCLEOSIDES WITH DUAL ANTI-HIV AND HBV ACTIVITY$195,507

R37 · FY2003 · AI

SYNTHESIS AND BIOTRANSFORMATION OF ANTI-VIRAL PRODRUGS$85,297

P51 · FY2003 · RR

NUCLEOSIDES WITH DUAL ANTI-HIV AND HBV ACTIVITY$194,177

R37 · FY2002 · AI

NUCLEOSIDES WITH DUAL ANTI-HIV AND HBV ACTIVITY$24,884

R37 · FY2002 · AI

NUCLEOSIDES WITH DUAL ANTI-HIV AND HBV ACTIVITY$192,000

R37 · FY2001 · AI

CORE--VIROLOGY FACILITY$0

P30 · FY2001 · DA

NUCLEOSIDES WITH DUAL ANTI-HIV AND HBV ACTIVITY$192,000

R37 · FY2000 · AI

CORE--VIROLOGY FACILITY$153,440

P30 · FY2000 · DA

DETERM URACIL IN RHESUS PLASMA, URINE &CEREBROSPINAL FLUID$39,712

P51 · FY2000 · RR